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CASE REPORT
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Valproate is an anticonvulsive drug whose mechanism of action is based on GABAergic systems. One of the infrequent adverse
effects of valproate is choreiform movements. In our study, we report a patient having head trauma history with partial and
secondary generalized seizures taking 1500 mg/day valproate. During the second month of the therapy, generalized chorea was
observed. Since other aetiologic causes of chorea were excluded, acutely occurring chorea in the patient was thought to be
related with valproate usage because of persistence of choreiform movements for days without any fluctuation. Valproate was
stopped slowly and lamotrigine was added at a dose of 400 mg/day. Within a two-month period after cessation of the valproate,
choreiform movements had disappeared. We thought that the history of head trauma and another antiepileptic drug usage were
the risk factors for the occurrence of valproate-induced choreiform movements.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Valproate (VPA) is an effective anticonvulsive drug
with a high tolerability. Its mechanism of action is
probably based on selective potentiation of gamma-
aminobutyric acid (GABA)-mediated postsynaptic
inhibition or on direct GABA increment in the brain1.
Animal studies have demonstrated that a mono-
unsaturated metabolite of VPA, δ2 valproic acid,
accumulates in selected regions of the brain: substantia
nigra, superior and inferior colliculus, hippocampus
and medulla2. Tremor is the most common adverse
effect (10%) of VPA on the central nervous system3.
Infrequent adverse effects of VPA include acute
encephalopathy with drowsiness, confusional states4
and asterixis; choreiform movements occurring within
30 minutes of taking VPA5; and sensorineural hearing
loss following chronic treatment6. In our study,
we report a patient with partial and secondarily
generalized seizures taking 1500 mg/day VPA. During
the second month of the therapy, generalized chorea
was observed which was completely reversible after
cessation of VPA.
CASE REPORT
A 38-year-old man was admitted to our clinic with
secondarily generalized seizures originating in the
temporal lobe. There was no family history of neu-
rological disease. His seizures started 15 years before
a traffic accident. He experienced his seizures during
sleep and the frequency of his seizures increased
with time. Originally he was taking carbamazepine.
VPA was added to the therapy. After taking VPA
1500 mg/day for two months (and still taking
carbamazepine), the patient complained of involuntary
movements. Neurologic examination was completely
normal except for visible choreiform movements
involving the trunk, head, and upper and lower
extremities. Laboratory examination including tests
of thyroid function, acute phase reactants, complete
blood count, electrolytes and arterial ammonia levels
were normal. His blood smear was free of acantho-
cytes. There were no epileptiform abnormalities on
interictal electroencephalography. Cranial magnetic
resonance imaging showed no abnormality. The serum
VPA level was 40 µg/dl. Since other aetiologic causes
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of chorea had been excluded, the acute chorea in
the patient was thought to be related to VPA usage
because of the persistence of choreiform movements,
day after day without any fluctuation. VPA was
withdrawn and lamotrigine was added eventually at a
dose of 400 mg/day. Two months after the cessation
of the VPA, choreiform movements had disappeared.
The patient has been seizure- and chorea-free since
that period.
DISCUSSION
Transient Parkinsonian symptoms associated with
VPA have already been reported in a few studies2, 6.
In these studies, the Parkinsonian symptoms were
reduced by levodopa plus carbidopa therapy and dis-
appeared completely two months after discontinuation
of VPA. The possible mechanism leading to the ap-
pearance of Parkinsonism during VPA treatment is not
known, but transient imbalance between functionally
reciprocal subgroups of GABA pathways leading to
dopamine inhibition has been suggested as part of
the aetiology of Parkinsonism induced by VPA7.
Choreiform movements associated with VPA usage
have been described more rarely than Parkinsonian
symptoms5. Lancman et al.5 presented three patients
who developed chorea during long-term treatment
with VPA. All the patients had severe brain damage
and one had a pre-existing unilateral vascular lesion in
the caudate nucleus. The choreic movements involved
the head, mouth, tongue, trunk and limbs bilaterally in
two cases and contralaterally in the patient with the
caudate lesion. Our case had had a head trauma 15
years ago, but his brain magnetic resonance imaging
did not reveal any lesion around his basal ganglia. The
VPA treatment was added while the patient was using
carbamazepine. The similarities between Lancman’s5
patients and our case were the history of brain injury
and other antiepileptic drug usage are known, together
with VPA. Lancman’s patients were taking phenytoin
in addition to VPA. Lancman concluded that VPA-
induced chorea might be more likely to develop if
VPA was taken together with phenytoin. We agree
with Lancman5 that sustained brain injury and any
other antiepileptic drug usage seem to be risk factors
for VPA-associated chorea. The chorea occurrence did
not correlate with VPA overdose in our case since the
blood level for VPA was in what is customarily said to
be the therapeutic range for VPA.
CONCLUSION
The mechanism underlying chorea associated with
VPA is, as yet, unclear. However, this rare adverse
effect of VPA is not a toxic effect and is reversible
by cessation of the drug. Patients with head trauma
using any other antiepileptic agent together with
VPA are at risk of having choreiform movements.
Carbamazepine as well as phenytoin increases the
risk of the development of VPA-associated choreiform
movements when used together with VPA.
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